KLK6 Antibody, FITC conjugated

1. High KLK6 expression is associated with metastasis of colon cancer. PMID:30015976
2. Results showed a significant downregulation of KLK6 mRNA expression in breast cancer (BC) tissue sections compared to the non-cancerous component. The expression of KLK6 is positively associated with tumor grade and is overexpressed in aggressive phenotypes such as TNBC. PMID:29435805
3. KLK6-PAR2 expression is down-regulated and PAR1 is up-regulated when DeltaNp63beta expression is decreased, leading to EMT with enhancing migration and invasion through ERK signal reduction at the invasive front PMID:29224812
4. KLK6 may be the key protease involved in the proteolytic modification of PFK-M. PMID:29563071
5. Our data demonstrate for the first time increased levels of KLK6 in mucosal melanomas of the head and neck PMID:27844409
6. Induction of autophagic processes through KLK6 expression may increase acquisition of resistance of gastric cancer cells to auranofin-induced autophagy. PMID:27863404
7. Our data provide experimental evidence that KLK6 controls metastasis formation in colon cancer via specific downstream network of miRNA-mRNA effectors. PMID:28431272
8. Data show that kallikrein 6 (KLK6) expression is induced in mouse and human skin during chronic glucocorticoid treatment. PMID:27283773
9. FST and KLK6 may have significance in breast cancer detection PMID:27168011
10. KLK6 overexpression and likely its proteolytic activity is associated with alterations in downstream miRNAs and their targets, and these differ with the molecular subtypes of breast cancer. PMID:27093921
11. Molecular models of peptides were built into the KLK6 structure and the marked preference of the cut between the two R of the examined peptides was related to the extended conformation of the substrates PMID:28254587
12. Our fine-mapping study has identified novel loci in the KLK6 region strongly associated with aggressive PCa. PMID:28376164
13. mRNA expression levels of KLK6 and KLK8 in advanced serous ovarian cancer PMID:27483364
14. Data indicate that elevated expression of microRNA-375 in head and neck squamous cell carcinoma (HNSCC) cells significantly reduces kallikrein 6 (KLK6), kallikrein 10 (KLK10), and matrix metalloproteinase 9 (MMP9) messenger RNA expression. PMID:26172508
15. KLK6 expression was detected in head and neck tumor cell lines (FaDu, Cal27 and SCC25), but not in HeLa cervix carcinoma cells. PMID:25990935
16. The results of this study indicated that reductions in kallikrein-6 and calpain-1 may contribute to the accumulation of alpha-synuclein in DLB. PMID:25476568
17. KLK6 and KLK10 may be useful markers and potential therapeutic targets in gastroesophageal junction tumors PMID:25649006
18. This study assessed the prognostic utility of human tissue kallikrein-like peptidases 6 and 10 (KLK6 and KLK10) and correlated their expression with histopathological and clinical parameters in gastric cancer. PMID:25153389
19. KLK6 may represent a potential unfavorable prognostic biomarker for colon cancer. PMID:25153391
20. KLK6 promotes the proliferation of lung tumoral cells and restrains their apoptosis in vitro via ligand-dependent EGFR and was dependent on the protease-activated receptor 2. PMID:24643912
21. The level of KLK6 is significantly increased in the plasma samples from laryngeal cancer patients compared to the controls. PMID:24669031
22. Our data suggest that de novo KLK6 expression during early liver carcinogenesis may induce production of Ubi(1-74) by post-translational modification of ubiquitin PMID:24979321
23. KLK6 mRNA expression could be considered as an independent, unfavorable molecular prognostic biomarker in colorectal adenocarcinoma, with additional prognostic value in patients without regional or distant metastases PMID:24430362
24. Data indicate there was no SNP in KLK6 was associated with altered risk of prostate cancer. PMID:21741862
25. Neuropathological analysis following delivery of LV-Neurosin to alpha-syn tg mice resulted in reduced accumulation of alpha-syn and reversal of neurodegenerative alterations in wild type but not A53T alpha-syn tg mice PMID:22508489
26. Patients with synucleinopathy displayed lower cerebrospinal fluid levels of neurosin and alpha-synuclein compared to controls and Alzheimer's disease patients. PMID:23308173
27. KLK6 DNA methylation was significantly associated with pathological stage in prostate cancer patients operated by radical prostatectomy. PMID:22874102
28. Decreased serum concentrations of KLK6 are found in patients with aneurysmal subarachnoid hemorrhage, with the lowest levels in patients who died PMID:23049835
29. hsa-let-7 family member hsa-let-7a is a modulator of KLK6 protein expression that is independent of the KLK6 copy number status PMID:23136250
30. KLK6 gene expression may have clinical utility as a marker of unfavorable prognosis for intracranial tumors, and consequently, it could be used as target for therapeutic intervention. PMID:22477710
31. in colorectal cancer patients, lymph node KLK6 positivity indicated presence of aggressive tumour cells associated with poor prognosis and high risk of tumour recurrence PMID:22699826
32. KLK6 is positioned to serve as a molecular trigger of select physiological processes involved in the development of astrogliosis PMID:22505518
33. KLK6 expressed by stromal cells may considerably contribute to the aggressiveness of ovarian cancer PMID:22505521
34. KLK6 is significantly upregulated and secreted in gastric cancer tissues and sera, suggesting that KLK6 might be used as a potential biomarker and therapeutic target for gastric cancer. PMID:22373580
35. KLK6 immunostaining is an independent prognostic marker in patients with colorectal carcinoma. PMID:22285222
36. High KLK6 is associated with ovarian cancer. PMID:22102857
37. KLK6-induced intracellular Ca(2+) flux and tumor cell invasion critically depends on the protease-activated receptor 1 (PAR1). PMID:21753781
38. KLK6 has a role in tumour proliferation and progression of NSCLC PMID:19426157
39. upregulated in late stage epithelial ovarian cancer PMID:20680316
40. KLK6 was up-regulated significantly in tissues and sera from patients with colon cancer and was associated closely with a poor prognosis. PMID:21656738
41. KLK6 promotes lymphocyte survival by a mechanism that depends in part on activation of PAR1. PMID:21464892
42. The expression of kallikrein 7 and kallikrein 6 in melanomas may be responsible for the loss of cell-cell adhesion. PMID:21193224
43. an altered KLK6 expression may contribute to vascular abnormalities in Alzheimer's disease and vascular dementia PMID:20846516
44. Neurosin targets extracellular alpha-synuclein in cultured cells. PMID:20403393
45. Patients diagnosed with advanced multiple sclerosis showed mean CSF levels of kallikrein-related peptidase 6 (29 ng/ml) that were significantly higher than in neurological controls (25.5 ng/ml). PMID:20836755
46. The expression of hK6 in ovarian cancer was higher than that in benign and borderline ovarian neoplasms. Expression is higher in the ovarian cancer of late stage, higher-grade, with lymph node metastasis and is associated with a poorer prognosis. PMID:19950700
47. KLK6 expression in cancerous tissues may play an important role in the invasion and metastasis of primary breast carcinoma. PMID:18992199
48. Data show that it was unable to distinguish men with and without prostate cancer using multiple kallikreins as urinary biomarkers. PMID:19560453
49. characterization of human kallikrein 6 as a degradative protease with structural features more similar to trypsin than the regulatory kallikreins PMID:11983703
50. X-ray crystallographic structure of KLK6. PMID:12016211

Show More

Hide All

HGNC: 6367

UNIGENE: Hs.79361

KEGG: hsa:5653

STRING: 9606.ENSP00000309148

OMIM: 602652